Don't bother with copy and paste.

Get this complete sample business plan as a free text document.

Download for free

Free Business Planning Webinar:

AI and Your Plan Register Now

Medical Support & Laboratories icon Medical Internet Marketing Business Plan

Start your plan

DocBuzz, Inc.

Executive Summary

DocBuzz, Inc. is a medical marketing company specializing in pharmaceutical, biotechnical and medical device detailing for the benefit of the medical community. DocBuzz, Inc. is the only company of its kind; a business especially designed for doctors and the medical community, owned and operated by practicing physicians.

The pharmaceutical market is one of the most profitable industries, with revenue in excess of $96.3 billion annually. The problem that the pharmaceutical industry has is simply time. Time for research and development, time for branding, time for marketing and sales, time to gain the trust and acceptance of the medical community. In this industry, we can equate time with money.

Two additional industries have similar situations with their products. Those industries are the biotech and the medical device companies. While the revenues are not as great as what one will find within the pharmaceutical industry, these companies face heavy competition within their own individual industries.

DocBuzz, Inc., has developed a method that allows all of these industries to benefit from prelaunch marketing, product branding, and postlaunch sales support–all accomplished with the direct intervention of practicing physicians. DocBuzz, Inc., gives the client companies the opportunity to market directly to the decision makers, establishing immediate credibility through our extensive network of physicians and other medical professionals. Providing live conferences, 24 hours a day, seven days a week, access to a myriad of current information on various pharmaceutical products, new biotech developments and medical devices, medical chat rooms, and online marketing make our e-detailing the most cost effective of any service offered.

The pharmaceutical, biotech and medical device industries will contract with DocBuzz, Inc., to provide marketing services, and because we are practicing physicians, we have immediate access to our colleagues. We can deliver these companies’ message directly to the decision makers for 75% of what these industries are currently budgeting. In addition, DocBuzz, Inc., by virtue of its unique incentive program will allow additional revenue to participating physicians and other medical practitioners.

DocBuzz has developed a winning strategy to provide the best and most up to date information to the medical community, while providing a method for these industries to announce, promote and market their products through respected practicing physicians. The individual professionals within the medical community benefit by receiving the most up to date industry information, all received via the Internet, and at the end of the e-detailing they will have the option to request samples, additional information on the product and/or the visit from a pharmaceutical company representative. Professionals on our medical panel can earn points by participating in our e-detailing and/or by referral of others who join our program.

1.1 Keys to Success

DocBuzz, Inc., has identified four key strategies that we feel are essential for success:

  1. Improve access of the prescribing doctor to the pharmaceuticals via newly developed Internet technology, to accelerate market acceptance of a product and to increase its prescribing pattern.
  2. DocBuzz, Inc., uses a grass root approach to recruit and retain participating prescribing medical professionals through a value incentive referral point program (VIRP). DocBuzz, Inc., as a physician owned and operated company, understands physician’s needs and offers, in addition to our unique VIRP system, other value added programs such as CME, physician cyber meeting places and other extensive point redemption options.
  3. DocBuzz, Inc. can provide evidence-based analysis for the pharmaceutical industry in order to justify the pharmaceutical investment in e-detailing.
  4. DocBuzz, Inc., anticipates aggressive, but controlled growth, in order to maintain the quality of our service.
Medical internet marketing business plan, executive summary chart image

1.2 Mission

DocBuzz, Inc., offers pharmaceutical, biotechnical and medical device manufacturers a reliable, high quality alternative to in-house resources for sales and marketing. DocBuzz, Inc., improves the return on sales and marketing investment by accelerating the physician learning curve on prelaunch, new, and existing products–through Web access to educational detailing and marketing research. In addition, DocBuzz, Inc., will benefit small and innovative biotechnology and pharmaceutical companies that do not have an extensive sales force to cover North America.

1.3 Objectives

  • To establish ourselves as a premier pharmaceutical e-detailing company, targeting medical professionals–i.e. physicians, nurse practitioners, physician assistants, dentists, and podiatrists.
  • We will offer value added services such as CME, current medical information updates, and physician meeting facilities (chat room and bulletin board).
  • To hire staff both currently identified and unidentified to implement our business concept.
  • To sign up 5% of the more than 650K prescribing medical professionals by year three, and provide 300K pharmaceutical detailing per year, by year three.
  • To reach a break-even point of $35,936 by the end of year two.
LivePlan Logo

See why 1.2 million entrepreneurs have written their business plans with LivePlan

Create Your Plan

Company Summary

Experienced physicians founded DocBuzz, Inc., as a company providing high-level expertise in e-detailing of pharmaceutical, biotechnical products and medical equipment to physicians and other medical professionals. It serves to capitalize the growing number of small and mid-sized companies as well as established larger companies to improve upon the awareness of pharmaceutical products and to increase the written prescription pattern of such products.

2.1 Company Ownership

DocBuzz, Inc., is a privately held Delaware corporation. Robert E. Rayder, MD, FAAP and Michael Y. Wu, MD, FAAP, are the founders and managing partners.

2.2 Start-up Summary

Total start-up expense (including legal cost, logo design, stationery and related expenses) comes to $99,000. The table below illustrates a complete breakdown of all start-up assets that are needed, as total start-up requirements. Currently, we have no short-term liabilities.

Medical internet marketing business plan, company summary chart image

Start-up Funding
Start-up Expenses to Fund $99,000
Start-up Assets to Fund $309,000
Total Funding Required $408,000
Assets
Non-cash Assets from Start-up $5,000
Cash Requirements from Start-up $304,000
Additional Cash Raised $0
Cash Balance on Starting Date $304,000
Total Assets $309,000
Liabilities and Capital
Liabilities
Current Borrowing $0
Long-term Liabilities $0
Accounts Payable (Outstanding Bills) $0
Other Current Liabilities (interest-free) $0
Total Liabilities $0
Capital
Planned Investment
Investor 1 $158,000
Investor 2 $250,000
Additional Investment Requirement $0
Total Planned Investment $408,000
Loss at Start-up (Start-up Expenses) ($99,000)
Total Capital $309,000
Total Capital and Liabilities $309,000
Total Funding $408,000
Start-up
Requirements
Start-up Expenses
Legal $3,000
Stationery etc. $20,000
Brochures $7,500
Consultants $20,000
Insurance $2,500
Rent $10,000
Research and Development $5,000
Expensed Equipment $30,000
Other $1,000
Total Start-up Expenses $99,000
Start-up Assets
Cash Required $304,000
Other Current Assets $5,000
Long-term Assets $0
Total Assets $309,000
Total Requirements $408,000

2.3 Company Locations and Facilities

DocBuzz, Inc., currently occupies a shared office space at 2476 North University Drive, Pembroke Pines, FL 33024. The current office provides sufficient space to launch the project; however, prior to implementation, separate facilities with easy access, and the ability to have the T-1 or T-4 connections will be required to implement our Internet program, which is the backbone of our business.

LivePlan Logo

See why 1.2 million entrepreneurs have written their business plans with LivePlan

Create Your Plan

Services

DocBuzz, Inc., offers e-detailing of pharmaceutical products and augmentation of pharmaceutical companies sales forces. According to the IMS Health Report, pharmaceutical detailing is a 50 billion dollar a year industry. Detailing is the portion of the pharmaceutical sales organization that provides information on new pharmaceutical products, face-to-face meetings with physicians, physician assistants, and nurse practitioners. Detailing is vital as new products are introduced, because the pharmaceutical companies must then make the medical professionals aware of the products, the method of administration, side effects and a myriad of other information. DocBuzz, Inc. offers the pharmaceutical companies the ability use e-detailing, which offers all of the benefits of the standard method of detailing, but with this difference: DocBuzz, Inc., uses the Internet, websites, personal referral networks, conferences, and Web conferences to achieve effective results at a lower cost to the pharmaceutical companies.

3.1 Service Description

DocBuzz, Inc., provides physician assisted marketing and sales of pharmaceutical products. Our service is vital during the pharmaceutical companies’ introduction of new products, the prelaunch of those products and increasing the present market share of existing products. Our company is physician owned, therefore, we have the understanding of the physicians’ needs in the current medical environment. In addition, physicians are more inclined to make a positive commitment when speaking to another physician as opposed to a pharmaceutical sales representative.

DocBuzz, Inc., provides a support infrastructure to pharmaceutical companies’ sales representatives nationwide by offering 24 hour, seven day a week service through our online literature and sampling requests.

Our company represents client companies, as an extension of its already established pharmaceutical sales force, not as a replacement. As a physician owned company, we understand first-hand our client’s endeavor to reach the busy, hurried medical provider, and the frustration and failure of missed contacts. We offer an additional tool to insure that the pharmaceutical company’s message is delivered and that the expenditure time with the medical professional is more productive. The physician will not have the time to listen to pharmaceutical sales representative but will make the time to talk to a trusted member of the medical community. More importantly, the product recommendations are considered more credible since the recommendation is coming from a physician. By using our Internet sampling request, physicians will make their needs known to us, and in turn, we pass that information directly to the sales representative. This increases the productivity of both the sales representative and the physician.

One of the tasks of a pharmaceutical company is to provide educational descriptions of their products to targeted physicians. This is most cost effectively achieved by the Internet’s 24/7 access availability, and our unique incentive program (VIRP). By associating with DocBuzz, pharmaceutical representatives, a vital part of the industries marketing and sales, could offer email response or telephone the physician at a more convenient time 24 hours a day, seven days a week.

3.2 Sales Literature

Literature, articles, product descriptions for all of the companies products we represent, and all of the other information that a practicing physician or other medical professional needs to know, will be available for immediate access through our Internet site.

Introductory information about our company will also be placed on our website, but detailed information describing our company and its positioning will be mailed to the medical professional prior to a DocBuzz, Inc., representative telephone conference or visit to the client’s facility.

3.3 Competitive Comparison

The competition comes in several forms.

Eric Rule, a partner with Cooper & Lybrand’s Integrated Healthcare Consulting Services practice, said, “With competition intensifying in the world’s pharmaceutical markets, being the first to market is crucial to securing a product’s success”. In the article Survey: Strategic issues facing the pharmaceutical industry, printed in Pharmaceutical Representative, dated April 17, 2001, one hundred-fifty senior pharmaceutical and biotechnology industry executives in the United States and Canada rated time-to-market for new products and making strategic alliances successful as number one and three respectively out of a list of twenty-three of the most important issues that face the pharmaceutical, biotech and medical device industries. The pharmaceutical industry has been dependant on their own in-house sales and marketing representatives to insure that the introduction of new products is successful.

The pharmaceutical industry is using net techniques to keep the rising cost of marketing their products to the medical community under control. Pharmaceutical companies are actively seeking to form strategic alliances with physicians both individually and collectively. “When industry leaders tell you that timely development of new products is the top key issue for the fifth consecutive year, you can be sure they’re pulling out all the stops to get differentiated products to the market ahead of the competition,” said Erik Rule. Andersen Consulting produced the report How Much are Marketing and Sales Capabilities Really Worth? What Every Pharmaceutical Executive Should Know. This report illustrates that within the pharmaceutical market, product differentiation overall is very small, so any differentiation must be driven through marketing and sales. The report shows that “42% [of the difference in operating margin] is explained by marketing and sales capabilities performance.” The report continues, “There are lots of me-too products in the market with very little differentiation. It is the job of marketing and sales to drive the differentiation.” The pharmaceutical industry is feeling the pure economic pressure of the market place, their shareholders demand increased profits and everything the company does costs money. The pharmaceutical companies’ need to reduce sales and marketing expense, while increasing their sales, is forcing them to try new methods, which translates into additional competition for our company.

Andersen Consulting surveyed 68 senior marketing and sales executives representing 18 large pharmaceutical companies in North America. The finding illustrates the pressure that the industry is experiencing. The difference between an average performance operating margin and the high performance-operating margin is 42%. That is not much of a difference, until one realizes that this is a one billion dollar industry, and if DocBuzz could simply improve a companies marketing and sales capability by 30%, that would translate into an additional $135 million in operating margin. The pharmaceutical industry generates $93.6 billion annually.

Our greatest competition comes from the pharmaceutical industry itself. The competitive pressure within the industry provides the perfect climate for us to launch our services. The industry has to make marketing and strategic alliance decisions so quickly, that markets are being ignored and these markets, when combined, are huge. For example, currently there is no e-detailing to the thousands of Physician Assistants and Nurse Practitioners. Research indicates that there are approximately 650,000 physicians in the United States; however, there is at least twice that number of Physician Assistants and Nurse Practitioners in the United States. The DocBuzz, Inc., target market, in addition to physicians, is to the physician assistants and nurse practitioners.

DocBuzz, Inc., has identified four start-up companies that are in various stages of development. These companies are:

  • RxCentric.com;
  • Busydoctor.com;
  • Hankyung.com (Korea only);
  • Skila.com;
  • PharmaDetailing.com;
  • MyDrugRep.com.

These businesses are focusing on e-detailing to the physician, but are not actively marketing to the physician assistants or nurse practitioners. In addition, we are the only company that is physician owned and operated. This difference is significant because as practicing physicians, we have the ability to reach the medical decision maker. As physicians, we have strong credibility when making a recommendation to a colleague. This ability will translate into increased prescription pattern of pharmaceutical products that we recommend.

3.4 Technology

DocBuzz, Inc., will have complete e-detailing facilities with the ability to prepare and deliver interactive multimedia presentations. We will have the capabilities to provide live chat, and prerecorded video presentations on a private and secured site.

DocBuzz, Inc., facilities house complete e-detailing operations, including the ability to prepare and deliver customized multimedia presentations. The ability to provide this type of interactive service is vital since it is one aspect of our company that separates us from our competition. As technology improves, the services we offer to the pharmaceutical, biotech and medical devices companies will grow as we incorporate the new improved technology.

3.5 Future Services

Once we achieve adequate market share in the United States, we will expand our operations to include South America, Japan, Israel, and Europe.

3.6 Fulfillment

DocBuzz, Inc., will provide consulting, sales and marketing service to the pharmaceutical industry. The pharmaceutical companies will pay an upfront fee for our consulting service. In addition, DocBuzz, Inc., will generate additional income streams by selling products that our clients produce; retaining the difference between the wholesale and the retail price of the product.

Additional detailed information regarding the sales forecast, unit price, sales, direct unit cost and direct cost of sales is found in the Sales Strategy section.

LivePlan Logo

See why 1.2 million entrepreneurs have written their business plans with LivePlan

Create Your Plan

Market Analysis Summary

Currently, the largest market segment is the pharmaceutical industry. In addition to pharmaceuticals, DocBuzz, Inc., will also target the fast growing biotechnical companies and medical device manufacturers. The market has demonstrated a sustained annual growth of approximately 11 percent. With this growth, the R and D costs will continue to increase. Through our prelaunch and marketing services, we will enable the pharmaceutical products to gain faster market share and increase their return on investment.

4.1 Market Segmentation

One of the most important marketing segments is the pharmaceutical industry, such as Pfizer, Glaxo-Welcome and Merck. Many companies have merged, acquiring controlling interest, forming strategic alliances, and placing others under exclusive contract and basically controlling the majority of this industry. DocBuzz, Inc., will work with these huge companies, but we will also work with the much smaller and lesser-known companies that have solid financial bases, but not the ability to overcome the budget and the in-house sales and marketing staff that the larger companies have. DocBuzz, Inc., will provide consultation, sales and marketing, and e-detailing support to all of these companies, regardless of size or market share.

Medical professionals comprise the key marketing component. Without this specific target market, the pharmaceutical, biotech and medical devices industries will disappear. All of our clients realize the importance of courting this one vital target market, the physician. DocBuzz, Inc., has a natural advantage in courting and delivering this segment for the benefit of all of the various markets we have targeted.

Biotech industry represents a smaller market in total revenue distributed for sales and marketing, compared to the pharmaceutical industry; however, this industry has shown a stable and quickly growing market.

Medical devices is the one sector that we will target that has the slowest growth. DocBuzz, Inc., is in a natural position to assist in the development of this industry, because we can open the doors that are closed to all but practicing members of the medical community. Companies that offer these services are vital to the medical community; however, until our company developed, this sector worked on the “old boy” network. Repairs are often sent to the manufacturer. The manufacturer provides long delays in returning the repaired equipment and it is often much more expensive than going to the companies that we represent.

Additionally, companies that are developing and marketing new medical devices need to have rapid entry into the market place. DocBuzz, Inc., provides this ability for the company that is manufacturing, conducting research and development, and any other company who needs to have immediate entry into the medical community. The marketing of service contracts will also increase through our efforts in the future.

Medical internet marketing business plan, market analysis summary chart image

Market Analysis
Year 1 Year 2 Year 3 Year 4 Year 5
Potential Customers Growth CAGR
Pharmaceutical Companies 14% 31 35 40 46 52 13.80%
Medical Professionals 14% 650,000 741,000 844,740 963,004 1,097,825 14.00%
Bio Tech 17% 1,000,000 1,170,000 1,368,900 1,601,613 1,873,887 17.00%
Medical Devices 7% 3,000,000 3,210,000 3,434,700 3,675,129 3,932,388 7.00%
Total 10.39% 4,650,031 5,121,035 5,648,380 6,239,792 6,904,152 10.39%

4.2 Target Market Segment Strategy

The building of a successful Internet e-detailing site is paramount for DocBuzz, Inc., to provide the quantity and quality of service that will insure total success of our venture. Each of our target markets uses the access to information that the Internet provides. DocBuzz, Inc., provides the much needed up-to-date information to the medical professional, then provides additional service by providing a sales and marketing representative to work directly with them.

Each of our target markets has specific needs that are unique to their own industry. DocBuzz, Inc., has focused on the common needs that each of these markets share. In addition to providing the services that fill our target markets’ needs, we also provide an economic incentive for the companies to choose our company.

Escalation of cost will continue within the research and development and sales and marketing. Each of our target markets share the same rising cost of developing a product for the market place, and then the actual marketing of the finished product. DocBuzz, Inc., provides for the more cost effective method of marketing finished products to the market place. The use of e-detailing provides instant access to qualified and interested decision makers within the medical community.

Additionally, DocBuzz, Inc. works with the company to provide market branding, strategic marketing, prelaunch and postlaunch consulting. Our services provide speed and access 24 hours a day, seven days a week, with the ability to download product information immediately. DocBuzz, Inc., representatives will follow up with these busy professionals and secure the sales that our client companies are looking for, at about 75% of the current sales and marketing expense that the companies are currently experiencing.

4.2.2 Market Growth

According to IMS Health marketing surveys, the pharmaceutical companies are enjoying between 10-15 percent annual growth. Additionally, the biotech industry has an annual growth rate of approximately 14% and the medical device industry is growing at about 7% per annum. With e-detailing we can increase the growth further.

LivePlan Logo

See why 1.2 million entrepreneurs have written their business plans with LivePlan

Create Your Plan

Strategy and Implementation Summary

The United States pharmaceutical market is the initial focus of DocBuzz, Inc., emphasizing the sale of pharmaceutical products to all targeted professionals. A special DocBuzz, Inc., liaison is assigned to the pharmaceutical company to evaluate their current market position, its strength and weaknesses. Then, DocBuzz, Inc., will design a complimentary e-marketing strategy and a targeted list of medical professional end users. Due to the shear amount of revenue that the pharmaceutical industry generates, this is the primary targeted industry. The quickly growing biotech and the less quick moving medical devices industries will receive similar service. Both of these industries require prelaunch marketing and focusing the medical community’s attention on the new products, the benefits that these new products will bring, and basically building market needs prior to the product’s official launch.

5.1 Competitive Edge

The pharmaceutical industry is now under increase pressure to improve profitability due to pressure from various non-pharmaceutical related entities. For example, traditionally the pharmaceutical industry is the body that will request changes of drug labeling (what the drug is approved for) such as prescription vs. over the counter, recently Well-Point a California HMO set a precedent by petitioning to the FDA to change three major top revenue generating prescription antihistamine to an over the counter status (Claritin, Zyrtec and Allegra). DocBuzz recognizes this development and will be in a position to assist the pharmaceutical industry to speed up through the use of prelaunch education and marketing to increase profit.

The key to successful e-detailing is an extensive, loyal and active medical professional. DocBuzz, Inc., is a physician owned company. This is a vital point. As practicing physicians, we know and understand the strategy to recruit and retain physicians. We have developed recruitment and retention tools, such as our unique VIRP, CME programs, chat rooms, live conferences and an extensive prize gallery. As practicing physicians, we better than anyone else, understand why a physician has certain prescribing habits and what will encourage that physician to change those habits.

Building this type of loyal network is a new business concept and several start-up companies are in various developmental stages that will provide similar services. These start-up companies’ strategy is to target the “top tier” pharmaceutical companies, with no other target markets. In addition to the “top tier” pharmaceutical companies, DocBuzz, Inc., also targets small- and medium-sized pharmaceutical, biotech and medical device companies. As a physician owned company, we have developed a unique retention program (VIRP) that caters to the needs of the physician.

Currently, there is no e-detailing to the thousands of ARNPs and PAs who prescribe millions of prescriptions yearly. DocBuzz, Inc., intends to market these significant physician extender as well. DocBuzz, Inc., plans on expanding our service to the thousands of physicians in training (interns, residents and medical students).

5.2 Marketing Strategy

DocBuzz, Inc., marketing strategy is the core of the main strategy:

  • DocBuzz, Inc., will utilize the principal’s personal contacts within the pharmaceutical, biotech and medical device industry.
  • All brochures and interactive CD presentations will be designed and created by DocBuzz, Inc.
  • Personal telephone calls by one of the physicians will follow every mailing of material.
  • Live presentations and question and answer sessions will be arranged by DocBuzz, Inc.

5.2.1 Pricing Strategy

DocBuzz, Inc., has developed a pricing strategy that provides a solid profit for our company, while providing good value for our client companies.

  • The industry average per face-to-face-detailing is $200, with poor to moderate effectiveness.
  • DocBuzz, Inc., provides e-detailing availability 24 hours a day, 7 days a week for the modest charge of $150 per e-detailing.
  • DocBuzz, Inc., offers discounts for high volume clients (package discounts).

5.2.2 Promotion Strategy

We depend on our extensive network of physicians and other professional contacts within the medical community. As the technology and our client industries change, we will change our strategies.

Networking and Support:

  • DocBuzz, Inc., will use contacts that are known to the principals of the company as a base on which to build our network core.
  • DocBuzz, Inc., will use the Internet to deliver literature mailing requests and real time demonstrations.
  • Literature mailing, phone sales, automated multimedia Power Point presentations, and personal visits by our principle physicians.

5.3 Sales Strategy

The specific sales strategy has been omitted due to critical internal information that is not for public disclosure. The specific sales strategy has been omitted due to critical internal information that is not for public disclosure. The specific sales strategy has been omitted due to critical internal information that is not for public disclosure. The specific sales strategy has been omitted due to critical internal information that is not for public disclosure. The specific sales strategy has been omitted due to critical internal information that is not for public disclosure.

5.3.1 Sales Forecast

The sales forecast monthly summary is included in the appendix. The annual sales projections are included here in the following table.

Medical internet marketing business plan, strategy and implementation summary chart image

Medical internet marketing business plan, strategy and implementation summary chart image

Sales Forecast
Year 1 Year 2 Year 3
Sales
Pharaceutical Companies $1,775,000 $1,900,000 $3,000,000
Medical Professionals $717,000 $500,000 $1,000,000
Bio-Tech $1,440,000 $430,000 $1,714,200
Medical Devices $600,000 $750,000 $850,000
Other $0 $234,800 $417,992
Total Sales $4,532,000 $3,814,800 $6,982,192
Direct Cost of Sales Year 1 Year 2 Year 3
Pharaceutical Companies $9,170 $20,000 $30,000
Medical Professionals $2,395 $25,000 $60,000
Bio-Tech $34,200 $43,000 $55,000
Medical Devices $24,000 $24,000 $24,000
Other $0 $0 $0
Subtotal Direct Cost of Sales $69,765 $112,000 $169,000

5.4 Strategic Alliances

  1. Professional groups such as the AMA and other specialty organizations.
  2. IMS Health (to capture individual data and physician prescription patterns).
  3. PEER GROUP is currently providing marketing/consulting through non-Internet media.
  4. Technology alliance (i.e. DELL, IBM, and ATT).
  5. Established Internet product distribution organizations–for example, Amazon.com, Buy.com, and various Travel sites.
  6. Other medical Internet sites for cross promotion.

5.5 Milestones

The table below indicates specific milestones that we feel are critical to our success.  The reader will notice that we listed each specific milestone, start and end date, budget allocated (if any) the specific person responsible for the successful accomplishment.  As each milestone is reached, it is deleted out of our plan, and replaced with a new milestone.

This is an example of why our business plan will never be complete, we view it as a living document that is in a constant state of change and growth.  We meet on a monthly basis, to review our milestones, and meet with our strategic consultants on a monthly basis, until such time as the consultants can be replaced with our own employees.

Milestones
Milestone Start Date End Date Budget Manager Department
Interview Plan Consultants 3/4/2001 5/1/2001 $0 Mike Wu Admin
Write Business Plan 5/3/2001 6/3/2001 $1,500 DFN Consultant
Presign Pharma companies 5/20/2001 7/5/2001 $600 Mike Wu Admin
Call Center Alliance 5/1/5393 7/5/2001 $0 DFN Consultant
Global-Outsource Call Center 7/5/2001 12/30/2001 $3,000 Christian Rose G-O President
Other 5/1/2001 12/30/2001 $0 Dr. Rayner Admin
Totals $5,100

LivePlan Logo

See why 1.2 million entrepreneurs have written their business plans with LivePlan

Create Your Plan

Management Summary

The company recognizes that initially we have management gaps. The company is seeking to fill these positions, and should the company require the services of one or more of these positions, the company will hire a consultant to fill the role of a virtual executive as the immediate need presents itself.

Robert E. Rayder, MD, FAAP Founder and Principal
Michael Y. Wu, MD, FAAP Founder and Principal

Dr’s. Rayder and Wu are university-trained pediatricians with a combined 35 years experience in successful private practice. They have significant involvement in the medical and pharmaceutical communities. Both hold faculty positions in several university/medical schools.

CEO (TBA): We are actively searching a dynamic individual MBA with both pharmaceutical and Internet expertise to manage the overall operation of the company.

IT Director (TBA): The IT director will oversee the IT development of the company including Web development.

CFO (TBA): The CFO will be in charge of the overall finance of the company.

Marketing Director (TBA): The marketing director will develop and implement the marketing plan of the company.

6.1 Management Team Gaps

We realize that we have major management team gaps; however, those gaps will be filled on a temporary basis by a virtual management team.  This team will be compensated for specific services that they have provided.  Using this method, the company will not feel pressured to hire someone that may not be a good fit with our company simply because they are qualified to fill the position.

6.2 Personnel Plan

The table below, contains the details of our personal plan. For the positions filled by virtual management, we have simply listed the office title that person holds.  When someone is hired by our company to fill one of these positions, their names will be inserted next to their title.

Personnel Plan
Year 1 Year 2 Year 3
Dr. Wu $75,000 $75,000 $82,500
Dr. Rayder $75,000 $75,000 $82,500
CEO $50,004 $50,004 $55,000
IT Director $39,996 $39,996 $44,000
Marketing Director $39,996 $39,996 $44,000
Secretary $22,800 $23,500 $25,000
Secretary 2 $0 $22,800 $23,500
Secretary 3 $0 $22,800 $23,500
Bookkeepter $0 $0 $22,800
Secretary 4 $0 $0 $22,800
Secretary 5 $0 $0 $28,000
CFO $50,004 $50,004 $55,000
Total People 7 9 12
Total Payroll $352,800 $399,100 $508,600

LivePlan Logo

See why 1.2 million entrepreneurs have written their business plans with LivePlan

Create Your Plan

Financial Plan

We are looking to fund a total package of $836,000 to support our growth plan, management style and vision. This total package has been broken into three phases, which is important to note, since at any time the management may decide that further funding is not necessary.

Our three-year sales projection shown below, profit and loss statement, cash flow analysis and balance sheet herein supports this financial plan.

7.1 Important Assumptions

The table below summarizes key financial assumptions.

General Assumptions
Year 1 Year 2 Year 3
Plan Month 1 2 3
Current Interest Rate 10.00% 10.00% 10.00%
Long-term Interest Rate 10.00% 10.00% 10.00%
Tax Rate 30.00% 30.00% 30.00%
Other 0 0 0

7.2 Key Financial Indicators

The following benchmark chart indicates our key financial indicators for the first three years. We project major growth in sales and operating expenses during times of expansion.

Medical internet marketing business plan, financial plan chart image

7.3 Break-even Analysis

The table below summarizes the break-even analysis. The break-even analysis has been calculated on the “burn rate” of the company. The company feels that this gives the investor a more accurate picture of the actual risk of the venture.

Medical internet marketing business plan, financial plan chart image

Break-even Analysis
Monthly Revenue Break-even $55,836
Assumptions:
Average Percent Variable Cost 2%
Estimated Monthly Fixed Cost $54,976

7.4 Projected Profit and Loss

The table and charts below summarize the profit and loss for the first three fiscal years.

Medical internet marketing business plan, financial plan chart image

Medical internet marketing business plan, financial plan chart image

Pro Forma Profit and Loss
Year 1 Year 2 Year 3
Sales $4,532,000 $3,814,800 $6,982,192
Direct Cost of Sales $69,765 $112,000 $169,000
Other Production Expenses $0 $0 $0
Total Cost of Sales $69,765 $112,000 $169,000
Gross Margin $4,462,235 $3,702,800 $6,813,192
Gross Margin % 98.46% 97.06% 97.58%
Expenses
Payroll $352,800 $399,100 $508,600
Sales and Marketing and Other Expenses $204,000 $214,000 $224,000
Depreciation $0 $0 $0
Leased Equipment $30,000 $30,000 $30,000
Utilities $0 $0 $0
Insurance $0 $0 $0
Rent $19,992 $20,000 $20,000
Payroll Taxes $52,920 $59,865 $76,290
Other $0 $0 $0
Total Operating Expenses $659,712 $722,965 $858,890
Profit Before Interest and Taxes $3,802,523 $2,979,835 $5,954,302
EBITDA $3,802,523 $2,979,835 $5,954,302
Interest Expense $0 $0 $0
Taxes Incurred $1,140,757 $893,951 $1,786,291
Net Profit $2,661,766 $2,085,885 $4,168,011
Net Profit/Sales 58.73% 54.68% 59.69%

7.5 Projected Cash Flow

Cash flow projections are critical to our success. The monthly cash flow is shown in the illustration, with one bar representing cash flow per month and the other representing the monthly balance. The annual cash flow figures are included here on the following table.

Medical internet marketing business plan, financial plan chart image

Pro Forma Cash Flow
Year 1 Year 2 Year 3
Cash Received
Cash from Operations
Cash Sales $4,532,000 $3,814,800 $6,982,192
Subtotal Cash from Operations $4,532,000 $3,814,800 $6,982,192
Additional Cash Received
Sales Tax, VAT, HST/GST Received $0 $0 $0
New Current Borrowing $0 $0 $0
New Other Liabilities (interest-free) $0 $0 $0
New Long-term Liabilities $0 $0 $0
Sales of Other Current Assets $0 $0 $0
Sales of Long-term Assets $0 $0 $0
New Investment Received $0 $0 $0
Subtotal Cash Received $4,532,000 $3,814,800 $6,982,192
Expenditures Year 1 Year 2 Year 3
Expenditures from Operations
Cash Spending $352,800 $399,100 $508,600
Bill Payments $1,395,906 $1,342,043 $2,225,381
Subtotal Spent on Operations $1,748,706 $1,741,143 $2,733,981
Additional Cash Spent
Sales Tax, VAT, HST/GST Paid Out $0 $0 $0
Principal Repayment of Current Borrowing $0 $0 $0
Other Liabilities Principal Repayment $0 $0 $0
Long-term Liabilities Principal Repayment $0 $0 $0
Purchase Other Current Assets $0 $0 $0
Purchase Long-term Assets $0 $0 $0
Dividends $0 $0 $0
Subtotal Cash Spent $1,748,706 $1,741,143 $2,733,981
Net Cash Flow $2,783,294 $2,073,657 $4,248,211
Cash Balance $3,087,294 $5,160,951 $9,409,162

7.6 Projected Balance Sheet

The balance sheet shows healthy growth of net worth and strong financial position. The monthly estimates are included in the appendix.

Pro Forma Balance Sheet
Year 1 Year 2 Year 3
Assets
Current Assets
Cash $3,087,294 $5,160,951 $9,409,162
Other Current Assets $5,000 $5,000 $5,000
Total Current Assets $3,092,294 $5,165,951 $9,414,162
Long-term Assets
Long-term Assets $0 $0 $0
Accumulated Depreciation $0 $0 $0
Total Long-term Assets $0 $0 $0
Total Assets $3,092,294 $5,165,951 $9,414,162
Liabilities and Capital Year 1 Year 2 Year 3
Current Liabilities
Accounts Payable $121,528 $109,300 $189,500
Current Borrowing $0 $0 $0
Other Current Liabilities $0 $0 $0
Subtotal Current Liabilities $121,528 $109,300 $189,500
Long-term Liabilities $0 $0 $0
Total Liabilities $121,528 $109,300 $189,500
Paid-in Capital $408,000 $408,000 $408,000
Retained Earnings ($99,000) $2,562,766 $4,648,651
Earnings $2,661,766 $2,085,885 $4,168,011
Total Capital $2,970,766 $5,056,651 $9,224,662
Total Liabilities and Capital $3,092,294 $5,165,951 $9,414,162
Net Worth $2,970,766 $5,056,651 $9,224,662

7.7 Business Ratios

The following table shows the projected business ratios. We expect to maintain healthy ratios for profitability, risk, and return. Industry profile ratios based on the Standard Industrial Classification (SIC) code 8742, Management Consulting Services, are shown for comparison.

Ratio Analysis
Year 1 Year 2 Year 3 Industry Profile
Sales Growth 0.00% -15.83% 83.03% 8.60%
Percent of Total Assets
Other Current Assets 0.16% 0.10% 0.05% 46.70%
Total Current Assets 100.00% 100.00% 100.00% 74.90%
Long-term Assets 0.00% 0.00% 0.00% 25.10%
Total Assets 100.00% 100.00% 100.00% 100.00%
Current Liabilities 3.93% 2.12% 2.01% 42.80%
Long-term Liabilities 0.00% 0.00% 0.00% 17.20%
Total Liabilities 3.93% 2.12% 2.01% 60.00%
Net Worth 96.07% 97.88% 97.99% 40.00%
Percent of Sales
Sales 100.00% 100.00% 100.00% 100.00%
Gross Margin 98.46% 97.06% 97.58% 0.00%
Selling, General & Administrative Expenses 39.73% 42.39% 37.88% 83.50%
Advertising Expenses 1.32% 1.83% 1.15% 1.20%
Profit Before Interest and Taxes 83.90% 78.11% 85.28% 2.60%
Main Ratios
Current 25.45 47.26 49.68 1.59
Quick 25.45 47.26 49.68 1.26
Total Debt to Total Assets 3.93% 2.12% 2.01% 60.00%
Pre-tax Return on Net Worth 128.00% 58.93% 64.55% 4.40%
Pre-tax Return on Assets 122.97% 57.68% 63.25% 10.90%
Additional Ratios Year 1 Year 2 Year 3
Net Profit Margin 58.73% 54.68% 59.69% n.a
Return on Equity 89.60% 41.25% 45.18% n.a
Activity Ratios
Accounts Payable Turnover 12.49 12.17 12.17 n.a
Payment Days 27 32 24 n.a
Total Asset Turnover 1.47 0.74 0.74 n.a
Debt Ratios
Debt to Net Worth 0.04 0.02 0.02 n.a
Current Liab. to Liab. 1.00 1.00 1.00 n.a
Liquidity Ratios
Net Working Capital $2,970,766 $5,056,651 $9,224,662 n.a
Interest Coverage 0.00 0.00 0.00 n.a
Additional Ratios
Assets to Sales 0.68 1.35 1.35 n.a
Current Debt/Total Assets 4% 2% 2% n.a
Acid Test 25.45 47.26 49.68 n.a
Sales/Net Worth 1.53 0.75 0.76 n.a
Dividend Payout 0.00 0.00 0.00 n.a

LivePlan Logo

See why 1.2 million entrepreneurs have written their business plans with LivePlan

Create Your Plan

Appendix

Sales Forecast
Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12
Sales
Pharaceutical Companies 0% $100,000 $125,000 $130,000 $135,000 $140,000 $145,000 $150,000 $155,000 $160,000 $165,000 $170,000 $200,000
Medical Professionals 0% $30,000 $60,000 $120,000 $150,000 $20,000 $22,000 $30,000 $35,000 $40,000 $50,000 $70,000 $90,000
Bio-Tech 0% $30,000 $30,000 $30,000 $30,000 $30,000 $30,000 $300,000 $300,000 $300,000 $300,000 $30,000 $30,000
Medical Devices 0% $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000 $50,000
Other 0% $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Total Sales $210,000 $265,000 $330,000 $365,000 $240,000 $247,000 $530,000 $540,000 $550,000 $565,000 $320,000 $370,000
Direct Cost of Sales Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12
Pharaceutical Companies $150 $100 $100 $120 $300 $500 $700 $900 $1,200 $1,500 $1,700 $1,900
Medical Professionals $150 $150 $150 $150 $150 $160 $160 $175 $200 $250 $250 $450
Bio-Tech $400 $400 $800 $900 $1,000 $1,300 $15,000 $2,000 $2,500 $3,000 $3,200 $3,700
Medical Devices $2,000 $2,000 $2,000 $2,000 $2,000 $2,000 $2,000 $2,000 $2,000 $2,000 $2,000 $2,000
Other $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Subtotal Direct Cost of Sales $2,700 $2,650 $3,050 $3,170 $3,450 $3,960 $17,860 $5,075 $5,900 $6,750 $7,150 $8,050
Personnel Plan
Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12
Dr. Wu 0% $6,250 $6,250 $6,250 $6,250 $6,250 $6,250 $6,250 $6,250 $6,250 $6,250 $6,250 $6,250
Dr. Rayder 0% $6,250 $6,250 $6,250 $6,250 $6,250 $6,250 $6,250 $6,250 $6,250 $6,250 $6,250 $6,250
CEO 0% $4,167 $4,167 $4,167 $4,167 $4,167 $4,167 $4,167 $4,167 $4,167 $4,167 $4,167 $4,167
IT Director 0% $3,333 $3,333 $3,333 $3,333 $3,333 $3,333 $3,333 $3,333 $3,333 $3,333 $3,333 $3,333
Marketing Director 0% $3,333 $3,333 $3,333 $3,333 $3,333 $3,333 $3,333 $3,333 $3,333 $3,333 $3,333 $3,333
Secretary 0% $1,900 $1,900 $1,900 $1,900 $1,900 $1,900 $1,900 $1,900 $1,900 $1,900 $1,900 $1,900
Secretary 2 0% $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Secretary 3 0% $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Bookkeepter 0% $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Secretary 4 0% $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Secretary 5 0% $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
CFO 0% $4,167 $4,167 $4,167 $4,167 $4,167 $4,167 $4,167 $4,167 $4,167 $4,167 $4,167 $4,167
Total People 7 7 7 7 7 7 7 7 7 7 7 7
Total Payroll $29,400 $29,400 $29,400 $29,400 $29,400 $29,400 $29,400 $29,400 $29,400 $29,400 $29,400 $29,400

General Assumptions
Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12
Plan Month 1 2 3 4 5 6 7 8 9 10 11 12
Current Interest Rate 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00%
Long-term Interest Rate 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00%
Tax Rate 30.00% 30.00% 30.00% 30.00% 30.00% 30.00% 30.00% 30.00% 30.00% 30.00% 30.00% 30.00%
Other 0 0 0 0 0 0 0 0 0 0 0 0

Pro Forma Profit and Loss
Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12
Sales $210,000 $265,000 $330,000 $365,000 $240,000 $247,000 $530,000 $540,000 $550,000 $565,000 $320,000 $370,000
Direct Cost of Sales $2,700 $2,650 $3,050 $3,170 $3,450 $3,960 $17,860 $5,075 $5,900 $6,750 $7,150 $8,050
Other Production Expenses $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Total Cost of Sales $2,700 $2,650 $3,050 $3,170 $3,450 $3,960 $17,860 $5,075 $5,900 $6,750 $7,150 $8,050
Gross Margin $207,300 $262,350 $326,950 $361,830 $236,550 $243,040 $512,140 $534,925 $544,100 $558,250 $312,850 $361,950
Gross Margin % 98.71% 99.00% 99.08% 99.13% 98.56% 98.40% 96.63% 99.06% 98.93% 98.81% 97.77% 97.82%
Expenses
Payroll $29,400 $29,400 $29,400 $29,400 $29,400 $29,400 $29,400 $29,400 $29,400 $29,400 $29,400 $29,400
Sales and Marketing and Other Expenses $17,000 $17,000 $17,000 $17,000 $17,000 $17,000 $17,000 $17,000 $17,000 $17,000 $17,000 $17,000
Depreciation $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Leased Equipment $2,500 $2,500 $2,500 $2,500 $2,500 $2,500 $2,500 $2,500 $2,500 $2,500 $2,500 $2,500
Utilities $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Insurance $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Rent $1,666 $1,666 $1,666 $1,666 $1,666 $1,666 $1,666 $1,666 $1,666 $1,666 $1,666 $1,666
Payroll Taxes 15% $4,410 $4,410 $4,410 $4,410 $4,410 $4,410 $4,410 $4,410 $4,410 $4,410 $4,410 $4,410
Other $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Total Operating Expenses $54,976 $54,976 $54,976 $54,976 $54,976 $54,976 $54,976 $54,976 $54,976 $54,976 $54,976 $54,976
Profit Before Interest and Taxes $152,324 $207,374 $271,974 $306,854 $181,574 $188,064 $457,164 $479,949 $489,124 $503,274 $257,874 $306,974
EBITDA $152,324 $207,374 $271,974 $306,854 $181,574 $188,064 $457,164 $479,949 $489,124 $503,274 $257,874 $306,974
Interest Expense $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Taxes Incurred $45,697 $62,212 $81,592 $92,056 $54,472 $56,419 $137,149 $143,985 $146,737 $150,982 $77,362 $92,092
Net Profit $106,627 $145,162 $190,382 $214,798 $127,102 $131,645 $320,015 $335,964 $342,387 $352,292 $180,512 $214,882
Net Profit/Sales 50.77% 54.78% 57.69% 58.85% 52.96% 53.30% 60.38% 62.22% 62.25% 62.35% 56.41% 58.08%

Pro Forma Cash Flow
Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12
Cash Received
Cash from Operations
Cash Sales $210,000 $265,000 $330,000 $365,000 $240,000 $247,000 $530,000 $540,000 $550,000 $565,000 $320,000 $370,000
Subtotal Cash from Operations $210,000 $265,000 $330,000 $365,000 $240,000 $247,000 $530,000 $540,000 $550,000 $565,000 $320,000 $370,000
Additional Cash Received
Sales Tax, VAT, HST/GST Received 0.00% $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
New Current Borrowing $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
New Other Liabilities (interest-free) $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
New Long-term Liabilities $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Sales of Other Current Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Sales of Long-term Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
New Investment Received $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Subtotal Cash Received $210,000 $265,000 $330,000 $365,000 $240,000 $247,000 $530,000 $540,000 $550,000 $565,000 $320,000 $370,000
Expenditures Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12
Expenditures from Operations
Cash Spending $29,400 $29,400 $29,400 $29,400 $29,400 $29,400 $29,400 $29,400 $29,400 $29,400 $29,400 $29,400
Bill Payments $2,466 $74,522 $91,098 $110,571 $119,559 $83,580 $89,110 $180,387 $174,755 $178,383 $180,868 $110,609
Subtotal Spent on Operations $31,866 $103,922 $120,498 $139,971 $148,959 $112,980 $118,510 $209,787 $204,155 $207,783 $210,268 $140,009
Additional Cash Spent
Sales Tax, VAT, HST/GST Paid Out $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Principal Repayment of Current Borrowing $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Other Liabilities Principal Repayment $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Long-term Liabilities Principal Repayment $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Purchase Other Current Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Purchase Long-term Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Dividends $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Subtotal Cash Spent $31,866 $103,922 $120,498 $139,971 $148,959 $112,980 $118,510 $209,787 $204,155 $207,783 $210,268 $140,009
Net Cash Flow $178,134 $161,078 $209,502 $225,029 $91,041 $134,020 $411,490 $330,213 $345,845 $357,217 $109,732 $229,991
Cash Balance $482,134 $643,212 $852,715 $1,077,744 $1,168,785 $1,302,805 $1,714,295 $2,044,508 $2,390,353 $2,747,570 $2,857,303 $3,087,294
Pro Forma Balance Sheet
Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12
Assets Starting Balances
Current Assets
Cash $304,000 $482,134 $643,212 $852,715 $1,077,744 $1,168,785 $1,302,805 $1,714,295 $2,044,508 $2,390,353 $2,747,570 $2,857,303 $3,087,294
Other Current Assets $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000 $5,000
Total Current Assets $309,000 $487,134 $648,212 $857,715 $1,082,744 $1,173,785 $1,307,805 $1,719,295 $2,049,508 $2,395,353 $2,752,570 $2,862,303 $3,092,294
Long-term Assets
Long-term Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Accumulated Depreciation $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Total Long-term Assets $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Total Assets $309,000 $487,134 $648,212 $857,715 $1,082,744 $1,173,785 $1,307,805 $1,719,295 $2,049,508 $2,395,353 $2,752,570 $2,862,303 $3,092,294
Liabilities and Capital Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12
Current Liabilities
Accounts Payable $0 $71,507 $87,424 $106,544 $116,775 $80,715 $83,090 $174,566 $168,815 $172,273 $177,198 $106,419 $121,528
Current Borrowing $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Other Current Liabilities $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Subtotal Current Liabilities $0 $71,507 $87,424 $106,544 $116,775 $80,715 $83,090 $174,566 $168,815 $172,273 $177,198 $106,419 $121,528
Long-term Liabilities $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Total Liabilities $0 $71,507 $87,424 $106,544 $116,775 $80,715 $83,090 $174,566 $168,815 $172,273 $177,198 $106,419 $121,528
Paid-in Capital $408,000 $408,000 $408,000 $408,000 $408,000 $408,000 $408,000 $408,000 $408,000 $408,000 $408,000 $408,000 $408,000
Retained Earnings ($99,000) ($99,000) ($99,000) ($99,000) ($99,000) ($99,000) ($99,000) ($99,000) ($99,000) ($99,000) ($99,000) ($99,000) ($99,000)
Earnings $0 $106,627 $251,789 $442,170 $656,968 $784,070 $915,715 $1,235,730 $1,571,694 $1,914,081 $2,266,373 $2,446,884 $2,661,766
Total Capital $309,000 $415,627 $560,789 $751,170 $965,968 $1,093,070 $1,224,715 $1,544,730 $1,880,694 $2,223,081 $2,575,373 $2,755,884 $2,970,766
Total Liabilities and Capital $309,000 $487,134 $648,212 $857,715 $1,082,744 $1,173,785 $1,307,805 $1,719,295 $2,049,508 $2,395,353 $2,752,570 $2,862,303 $3,092,294
Net Worth $309,000 $415,627 $560,789 $751,170 $965,968 $1,093,070 $1,224,715 $1,544,730 $1,880,694 $2,223,081 $2,575,373 $2,755,884 $2,970,766

LivePlan Logo

See why 1.2 million entrepreneurs have written their business plans with LivePlan

Create Your Plan